Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Capital Expenditures (2019 - 2025)

Keros Therapeutics filings provide 7 years of Capital Expenditures readings, the most recent being -$1.4 million for Q4 2025.

  • On a quarterly basis, Capital Expenditures fell 588.58% to -$1.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $5000.0, a 99.74% decrease, with the full-year FY2025 number at $5000.0, down 99.74% from a year prior.
  • Capital Expenditures hit -$1.4 million in Q4 2025 for Keros Therapeutics, down from $1.4 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $1.6 million in Q3 2024 to a low of -$1.4 million in Q4 2025.
  • Median Capital Expenditures over the past 5 years was $159000.0 (2021), compared with a mean of $252631.6.
  • Biggest five-year swings in Capital Expenditures: surged 2471.43% in 2021 and later crashed 11836.36% in 2023.
  • Keros Therapeutics' Capital Expenditures stood at $159000.0 in 2021, then soared by 672.33% to $1.2 million in 2022, then crashed by 56.11% to $539000.0 in 2023, then tumbled by 46.38% to $289000.0 in 2024, then crashed by 588.58% to -$1.4 million in 2025.
  • The last three reported values for Capital Expenditures were -$1.4 million (Q4 2025), $1.4 million (Q3 2025), and -$551000.0 (Q2 2025) per Business Quant data.